You are here:

daptomycin (Cubicin)

Advice

In the absence of a submission from the holder of the marketing authorisation:

daptomycin (Cubicin®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia associated with complicated skin and soft-tissue infections.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: daptomycin (Cubicin)
SMC Drug ID: 1309/18
Manufacturer: MSD
Indication: Treatment of paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia associated with complicated skin and soft-tissue infections.
BNF Category:
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 12 February 2018

Back